Opinion
Video
Daniel Bowles, MD, discusses the toxicity profiles and adverse reactions associated with frontline and second-line treatments for differentiated thyroid cancer (DTC).
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress